Ramsay Santé: The Numbers Are Improving While the Market Still Prices Fear

Ramsay Santé is a European private hospital operator that generates €5.4 billion a year in revenue across 492 facilities in France and the Nordic countries. It reported its fiscal 2026 results on August 26 — and the headline numbers tell a story most investors haven't started pricing in yet. Revenue grew 3.3%. EBITDA margin rose to 11.9%, up from 11.5% a year earlier when you strip out one-time French government subsidies. The net loss narrowed from €54 million to €48 million. Leverage, the number that keeps investors and credit ratings agencies up at night, held steady at 4.7 times EBITDA.

The market has written this business off as a high-debt operator strangled by French government tariffs. The stock trades at a market capitalization of roughly €1.2 billion against €3.6 billion of net financial debt. Moody's carries it at B1 with a negative outlook. The negative P/E ratio, the junk-bond credit rating, the persistent government funding fights — it is an unappealing picture.

But the operating setup underneath that picture is not breaking. It is getting measurably better.

The cash-flow path is where the story actually lives. Free cash flow — the money left after the business pays its bills and funds the equipment and buildings that keep hospitals running — is the preferred proof point for whether an operator is genuinely improving or just rearranging its balance sheet.

Here is where Ramsay Santé sits. Operating cash flow for fiscal 2026 was €525 million. That is down from €694 million a year earlier, and that decline is the one number that deserves scrutiny. The cause was not worse operations. It was working capital normalization — specifically, lower French state cash advances and changes to a factoring scheme. In the prior year, timing of government payments inflated operating cash flow by roughly €100 million. This year, that timing advantage reversed. The underlying cash-generating engine did not weaken.

Capital expenditure held at €144 million, broadly unchanged from the prior year. So on a normal working-capital basis, the free cash flow generation is closer to €380 million than the raw numbers suggest. That is the financial bridge: an operator with €5.4 billion in revenue generating roughly €380 million in free cash flow against €1.6 billion of net debt on a pre-IFRS16 basis (the company uses this restated measure for leverage because IFRS 16 lease accounting inflates debt by roughly €2 billion in operating lease obligations that behave more like long-term operating commitments than bank debt).

The government funding problem is real, and it is the single biggest risk. France sets the reimbursement tariffs for hospital services, and those tariffs have not kept pace with medical staff salary inflation, procurement costs, or wage growth. In fiscal 2026, MSO (medicine, surgery, obstetrics) tariffs received a 0.5 percent increase in March 2025 and zero increase from January 2026. The French government also cut back its revenue guarantee program, creating an estimated €20 million shortfall.

Most investors read this as a structural margin killer. The operating data reads differently. Despite all of that, Ramsay Santé expanded its EBITDA margin from 11.5 percent to 11.9 percent. France MSO admissions grew 2.5 percent. The company opened three mental health day centers and installed 11 new imaging units. Efficiency programs — staffing optimization, medical purchase savings, administrative cost controls — are absorbing what tariff growth does not cover.

The mechanism here is important to understand. When a hospital operator faces a tariff squeeze, there are two paths: margins compress and the business deteriorates, or the operator squeezes productivity until the cost base bends. Ramsay Santé has been executing the second path for two years now. The "Yes We Care" strategic plan, which the company says is nearing completion, is the internal name for this productivity drive. It is not a magic bullet — cost inflation and tariff freezes are genuinely difficult structural constraints — but the fact that margins are expanding despite them is the evidence that the cost base is flexible enough to hold.

There is a second story that most retail investors have not encountered because Ramsay Santé trades on the Euronext Paris exchange, not on a U.S. venue. That may change.

Ramsay Health Care, the Australian parent company that owns 52.79 percent of Ramsay Santé, has proposed distributing its stake to RHC shareholders through an in-specie distribution — meaning shareholders would receive Ramsay Santé shares directly rather than cash. The deal is expected to close in December 2026, subject to approvals. Ramsay Santé plans to apply for a foreign exempt listing on the Australian Securities Exchange, giving shareholders access through CHESS Depositary Interests.

Why does this matter? Because the demerger separates Ramsay Santé from a holding company that has carried a discount to the combined value of its subsidiaries. A standalone Ramsay Santé with its own investor base, its own capital markets presence, and its own governance may trade at a different multiple than it does as a partially-owned subsidiary. Whether that multiple is higher or lower is not predetermined — but it is a re-rating event that has a specific date on the calendar.

The debt refinancing that closed in July 2026 — €1.75 billion in senior debt, with maturities extended from 2031 to 2033 — was structured specifically to accommodate this distribution. The change-of-control provisions were written to survive it. This is not a company that is scrambling to hold its capital structure together. It is actively reorganizing for independence.

Then there is the St. Göran hospital contract, the one piece of contracted revenue that changes the visibility on the Nordic business. In October 2024, Capio — Ramsay Santé's Swedish subsidiary — was awarded the contract to manage Stockholm's largest private hospital. The deal is valued at €4.8 billion over 12 years, with improved price terms and indexation. It began on January 5, 2026. That is €400 million a year of contracted revenue with price escalation built in, running through at least 2034. Only one of three qualified bidders submitted a tender. The other two declined.

This contract matters because it transforms a portion of the Nordic revenue from a fee-for-service model into a long-term contracted stream with visibility. In a business where French government policy can shift the margin outlook overnight, having half a billion euros of annualized Nordic revenue locked into an indexed contract is a meaningful hedge.

Now for the numbers that keep investors away. Net financial debt on an IFRS basis is €3.6 billion. Leverage on a restated pre-IFRS16 basis is 4.7x EBITDA. Moody's calls it B1 with negative outlook. The company posted a net loss for the fifth consecutive fiscal year. There has been no dividend.

The leverage is high. That is not a matter of opinion. But it is stable, not rising, and it is stable while the EBITDA denominator is growing. A year ago it was 4.7x. Two years ago it was 4.9x. The trajectory is flat-to-improving, and the debt maturities have just been pushed to 2033. Moody's stated clearly in May 2025 that a stable outlook would require "sustained revenue growth and profitability improvements to restore stronger credit metrics." Ramsay Santé's latest results are exactly that — 3.3 percent revenue growth, expanding margins, a narrowing net loss. The credit story may still be two quarters from turning positive, but the direction is no longer in question.

The net losses are accounting losses, driven by IFRS 16 lease depreciation and interest expense on €3.6 billion of debt. They do not reflect the operating cash generation. EBITDA is €638 million. The current operating result (the closest GAAP-adjacent profit measure before depreciation) was positive for a fifth consecutive year. The business is operating profitably. The losses exist because of how the capital structure and lease accounting interact with the income statement. That is a real constraint — interest expense is real, and debt eventually matures — but it is not an operating failure.

Here is the situation in one frame. The market is still pricing the old risk profile while the operating setup is already getting cleaner. Revenue growth is holding in the low-single digits. Margins are expanding despite French government tariff pressure. The debt is heavy but stable, and the maturities have been extended. A €400 million-per-year contracted revenue stream in Sweden is running. The demerger from the Australian parent is scheduled for December. The Capital Markets Day on September 17, when management will present the 2030 strategy, may be the first time investors see a standalone financial roadmap rather than a subsidiary's line-item in a holding-company report.

This is not about excitement. It is about a business that may look harder to dismiss once the full operating trajectory becomes visible.

The bear case deserves its plain statement. The French government funding gap is structural, not cyclical. If tariffs remain flat while salary inflation resumes, the margin expansion reverses. The cost-base flexibility that has held for two years can break. At 4.7x leverage, there is no room for a meaningful EBITDA decline without triggering covenant scrutiny or a ratings downgrade. Moody's already has a negative outlook. If free cash flow does not compound toward that €380 million normal range, the leverage becomes a real constraint rather than an accounting one.

The thesis breaks if the next set of quarterly results shows contracting EBITDA margins, widening losses, or a leverage ratio that moves above 5.0x on a restated basis. Any of those would mean the cost structure has stopped bending and the government squeeze is winning. The specific condition that must hold for the re-rating story to survive is simple: EBITDA margin must continue expanding or at least hold steady, and free cash flow must normalize once the working capital effects reverse.

There is no DCF that resolves this. There is no spreadsheet that tells you whether the French government will raise tariffs next year. The forward EBITDA multiple on consensus estimates of roughly €650 million for fiscal 2027 puts enterprise value at approximately 7.3x forward EBITDA — not cheap by any standard, but that multiple already reflects the debt, the rating, and the government risk. The upside, if it comes, does not come from the multiple expanding on its own. It comes from EBITDA growing faster than the market expects while leverage falls, and from the demerger unlocking a standalone trading multiple.

The setup is a business improving underneath a depressed narrative, with a specific calendar event — the December demerger and the September Capital Markets Day — that forces investors to re-examine it. The financial proof is the EBITDA margin trajectory and the free cash flow normalization. If those continue, the story writes itself. If they break, there is no argument that survives.